Immunodominance of Lytic Cycle Antigens in Epstein-Barr Virus-Specific CD4+ T Cell Preparations for Therapy

• Dinesh Adhikary,

  Affiliations Clinical Cooperation Group, Institute for Clinical and Molecular Biology, GSF-National Research Center for Environment and Health, Munich, Germany, Children's Hospital, Hematology-Oncology, University of Technology, Munich, Germany

  ⨯
• Uta Behrends,

  Affiliations Clinical Cooperation Group, Institute for Clinical and Molecular Biology, GSF-National Research Center for Environment and Health, Munich, Germany, Children's Hospital, Hematology-Oncology, University of Technology, Munich, Germany

  ⨯
• Heike Boerschmann,

  Affiliation Children's Hospital, Hematology-Oncology, University of Technology, Munich, Germany

  ⨯
• Andrea Pfünder,

  Affiliation Children's Hospital, Hematology-Oncology, University of Technology, Munich, Germany

  ⨯
• Stefan Burdach,

  Affiliation Children's Hospital, Hematology-Oncology, University of Technology, Munich, Germany

  ⨯
• Andreas Moosmann,

  Affiliation Clinical Cooperation Group Molecular Oncology, Department of Gene Vectors, GSF-National Research Center for Environment and Health and Department of Otorhinolaryngology, Ludwig Maximilians University, Munich, Germany

  ⨯
• Klaus Witter,

  Affiliation Laboratory of Immunogenetics, Ludwig Maximilians University, München, Germany

  ⨯
• Georg W. Bornkamm,

  Affiliation Clinical Cooperation Group, Institute for Clinical and Molecular Biology, GSF-National Research Center for Environment and Health, Munich, Germany

  ⨯
• Josef Mautner

  *To whom correspondence should be addressed. E-mail: mautner@gsf.de

  Affiliations Clinical Cooperation Group, Institute for Clinical and Molecular Biology, GSF-National Research Center for Environment and Health, Munich, Germany, Children's Hospital, Hematology-Oncology, University of Technology, Munich, Germany

  ⨯